中国药物警戒 ›› 2026, Vol. 23 ›› Issue (4): 473-475.
DOI: 10.19803/j.1672-8629.20250389

• 安全与合理用药 • 上一篇    下一篇

苹果酸舒尼替尼胶囊致下消化道出血1例分析

司刘哲1, 邓瑞2, 刘琪2, 原明亮2, 屈冰2, 张爱玲1, 韩雪1, 柴玉娜1,*   

  1. 1郑州大学第一附属医院药学部,河南 郑州 450000;
    2郑州大学第一附属医院胃肠外科,河南 郑州 450000
  • 收稿日期:2025-06-16 出版日期:2026-04-15 发布日期:2026-04-15
  • 通讯作者: *柴玉娜,女,博士,副主任药师,药理学与中药药理学。E-mail: yuna999@126.com
  • 作者简介:司刘哲,女,在读硕士,药理学与中药药理学。
  • 基金资助:
    河南省自然科学基金资助项目（242300421271）; 海峡两岸医药卫生交流协会青年科研基金（2024-06）

One Case of Lower Gastrointestinal Bleeding Caused by Sunitinib Malate Capsules

SI Liuzhe1, DENG Rui2, LIU Qi2, YUAN Mingliang2, QU Bing2, ZHANG Ailing1, HAN Xue1, CHAI Yuna1,*   

  1. 1Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan 450000, China;
    2Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan 450000, China
  • Received:2025-06-16 Online:2026-04-15 Published:2026-04-15

PDF (PC)

45

摘要： 目的 探讨苹果酸舒尼替尼胶囊（以下简称“舒尼替尼胶囊”）致消化道出血的不良反应病例,为临床舒尼替尼胶囊的安全用药提供参考。方法 以临床药师发现的1例62岁女性患者,因胃肠间质瘤肝转移服用舒尼替尼胶囊后出现下消化道出血的临床病例为基础,并查阅国内外相关资料对其出血原因进行分析。结果 舒尼替尼胶囊致患者发生消化道出血为“很可能”,可能为舒尼替尼胶囊抑制血管内皮生长因子而导致血管正常生理功能的受限及血小板功能和纤维蛋白形成被抑制。结论 临床应警惕舒尼替尼胶囊引起的消化道出血,重启该药物治疗时应权衡其利弊,加强监护,保障患者用药安全。

关键词: 苹果酸舒尼替尼胶囊, 酪氨酸激酶抑制剂, 下消化道出血, 药品不良反应

Abstract: Objective To analyze one case of adverse drug reactions–gastrointestinal bleeding–caused by sunitinib Malate Lepsules, and to provide a reference for safe use of sunitinib in clinical practice. Methods Based on a clinical case of a 62-year-old female patient who developed lower gastrointestinal bleeding after taking sunitinib capsules due to gastrointestinal stromal tumor with liver metastasis, clinical pharmacists consulted related literature and analyzed the causes of bleeding. Results Gastrointestinal bleeding of the patient was determined as a “probable” adverse drug reaction to sunitinib capsules. The mechanism might be that vascular endothelial growth factors were inhibited by sunitinib, leading to the impairment of normal vascular physiological functions and the inhibition of platelet function and fibrin formation. Conclusion Clinicians should remain vigilant on gastrointestinal bleeding caused by sunitinib during medication. When a therapy with this drug is used a second time, the risks and benefits must be weighed, and patients should be monitored to ensure the safety of medication.

Key words: Sunitinib Malate Capsules, Tyrosine Kinase Inhibitors, Lower Gastrointestinal Bleeding, Adverse Drug Reaction

中图分类号: